###begin article-title 0
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUS-DDIT3</italic>
FUS-DDIT3 Prevents the Development of Adipocytic Precursors in Liposarcoma by Repressing PPARgamma and C/EBPalpha and Activating eIF4E
###end article-title 0
###begin p 1
Conceived and designed the experiments: IS. Performed the experiments: BP PP CB FA MS. Analyzed the data: BP IS PP CB FA MS. Wrote the paper: IS PP.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
FUS-DDIT3 is a chimeric protein generated by the most common chromosomal translocation t(12;16)(q13;p11) linked to liposarcomas, which are characterized by the accumulation of early adipocytic precursors. Current studies indicate that FUS-DDIT3- liposarcoma develops from uncommitted progenitors. However, the precise mechanism whereby FUS-DDIT3 contributes to the differentiation arrest remains to be elucidated.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 195 202 187 194 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 97 112 <span type="species:ncbi:10090">transgenic mice</span>
###xml 228 233 <span type="species:ncbi:9606">human</span>
###xml 679 683 <span type="species:ncbi:10090">mice</span>
###xml 688 693 <span type="species:ncbi:9606">human</span>
###xml 977 992 <span type="species:ncbi:10090">transgenic mice</span>
Here we have characterized the adipocyte regulatory protein network in liposarcomas of FUS-DITT3 transgenic mice and showed that PPARgamma2 and C/EBPalpha expression was altered. Consistent with in vivo data, FUS-DDIT3 MEFs and human liposarcoma cell lines showed a similar downregulation of both PPARgamma2 and C/EBPalpha expression. Complementation studies with PPARgamma but not C/EBPalpha rescued the differentiation block in committed adipocytic precursors expressing FUS-DDIT3. Our results further show that FUS-DDIT3 interferes with the control of initiation of translation by upregulation of the eukaryotic translation initiation factors eIF2 and eIF4E both in FUS-DDIT3 mice and human liposarcomas cell lines, explaining the shift towards the truncated p30 isoform of C/EBPalpha in liposarcomas. Suppression of the FUS-DDIT3 transgene did rescue this adipocyte differentiation block. Moreover, eIF4E was also strongly upregulated in normal adipose tissue of FUS-DDIT3 transgenic mice, suggesting that overexpression of eIF4E may be a primary event in the initiation of liposarcomas. Reporter assays showed FUS-DDIT3 is involved in the upregulation of eIF4E in liposarcomas and that both domains of the fusion protein are required for affecting eIF4E expression.
###end p 5
###begin title 6
Conclusions/Significance
###end title 6
###begin p 7
###xml 187 196 187 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUS-DDIT3</italic>
Taken together, this study provides evidence of the molecular mechanisms involve in the disruption of normal adipocyte differentiation program in liposarcoma harbouring the chimeric gene FUS-DDIT3.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 111 114 111 114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-US1">[1]</xref>
###xml 116 119 116 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Mack1">[2]</xref>
###xml 226 235 226 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUS-DDIT3</italic>
###xml 245 248 245 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Aman1">[3]</xref>
###xml 249 252 249 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Rabbitts1">[5]</xref>
###xml 307 310 307 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUS</italic>
###xml 359 362 359 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TLS</italic>
###xml 406 411 406 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">DDIT3</italic>
###xml 437 440 437 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Crozat1">[4]</xref>
###xml 442 445 442 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Rabbitts1">[5]</xref>
###xml 535 538 535 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Prasad1">[6]</xref>
###xml 540 543 540 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-SanchezGarcia1">[7]</xref>
###xml 745 748 745 748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Ron1">[8]</xref>
###xml 749 753 749 753 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Goransson1">[12]</xref>
###xml 755 764 755 764 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUS-DDIT3</italic>
###xml 840 843 840 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Aman1">[3]</xref>
###xml 844 847 844 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Rabbitts1">[5]</xref>
Myxoid/round cell liposarcoma is the most common subtype of liposarcoma, accounting for about 40% of all cases [1], [2]. The tumor cells are characterized by the chromosomal translocation t(12;16)(q13;p11), which produces the FUS-DDIT3 oncogene [3]-[5]. This oncogene consists of the NH2-terminal domain of FUS (previously termed translocated in liposarcoma, TLS) fused to the entire codifying sequence of DDIT3 (previously termed CHOP) [4], [5]. The NH2-terminal domain of FUS confers the transactivation domain to the fusion protein [6], [7]. DDIT3 is a member of the C/EBP family of transcription factors which contains a basic leucine zipper domain and a DNA binding domain, able to form heterodimers with and inactivate other C/EBP members [8]-[12]. FUS-DDIT3 has not been found in tumor types other than myxoid/round cell liposarcoma [3]-[5].
###end p 9
###begin p 10
###xml 6 14 6 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 97 101 97 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Zinszner1">[13]</xref>
###xml 369 373 366 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Adelmant1">[14]</xref>
###xml 446 454 443 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 490 494 487 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Batchvarova1">[15]</xref>
###xml 495 499 492 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-ThelinJarnum1">[16]</xref>
###xml 692 696 689 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-PerezLosada1">[17]</xref>
###xml 698 702 695 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-PerezLosada2">[18]</xref>
###xml 852 860 849 857 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 956 960 953 957 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Engstrom1">[19]</xref>
###xml 1077 1086 1074 1083 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUS-DDIT3</italic>
###xml 1200 1204 1193 1197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-PerezMancera1">[20]</xref>
###xml 1337 1346 1330 1339 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUS-DDIT3</italic>
###xml 1431 1435 1424 1428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Riggi1">[21]</xref>
###xml 1612 1616 1605 1609 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-PerezMancera2">[22]</xref>
###xml 1784 1791 1777 1784 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1952 1961 1945 1954 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUS-DDIT3</italic>
###xml 2097 2101 2086 2090 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Riggi1">[21]</xref>
###xml 2196 2200 2185 2189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-PerezLosada1">[17]</xref>
###xml 2237 2246 2226 2235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUS-DDIT3</italic>
###xml 2669 2673 2658 2662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-PerezMancera1">[20]</xref>
###xml 2834 2838 2823 2827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-PerezLosada2">[18]</xref>
###xml 3082 3090 3071 3079 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 3090 3094 3079 3083 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Engstrom1">[19]</xref>
###xml 3260 3264 3249 3253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-PerezMancera2">[22]</xref>
###xml 3307 3316 3296 3305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUS-DDIT3</italic>
###xml 3441 3445 3430 3434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-SnchezGarca1">[23]</xref>
###xml 3446 3450 3435 3439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-PrezMancera1">[24]</xref>
###xml 512 517 <span type="species:ncbi:10090">mouse</span>
###xml 580 595 <span type="species:ncbi:10090">transgenic mice</span>
###xml 801 806 <span type="species:ncbi:9606">human</span>
###xml 1057 1061 <span type="species:ncbi:10090">mice</span>
###xml 1587 1592 <span type="species:ncbi:9606">human</span>
###xml 1886 1891 <span type="species:ncbi:9606">human</span>
###xml 1925 1940 <span type="species:ncbi:10090">transgenic mice</span>
###xml 2119 2134 <span type="species:ncbi:10090">transgenic mice</span>
###xml 2178 2183 <span type="species:ncbi:9606">human</span>
###xml 2263 2267 <span type="species:ncbi:10090">mice</span>
###xml 2535 2550 <span type="species:ncbi:10090">transgenic mice</span>
###xml 2685 2689 <span type="species:ncbi:10090">mice</span>
###xml 2954 2958 <span type="species:ncbi:10090">mice</span>
Early in vitro approaches have shown the transforming effects of FUS-DDIT3 in NIH-3T3 fibroblast [13], but not in 3T3-L1 preadipocytes, suggesting that the activity of FUS-DDIT3 was influenced by the cellular environment. Moreover, it has been demonstrated that FUS-DDIT3 blocks the adipogenic potential of NIH-3T3 fibroblast by interfering with the C/EBPbeta activity [14]. The ability of FUS-DDIT3 to block adipocyte differentiation is shared, in vitro, for DDIT3 in 3T3-L1 preadipocytes [15]-[16], but not in mouse embryonic fibroblasts (MEFs) derived from FUS-DDIT3 and DDIT3 transgenic mice, where FUS-DDIT3, but not DDIT3, is able to block the adipocyte differentiation program in MEFs [17], [18]. However, FUS-DDIT3 shares with DDIT3 the capacity to induce liposarcomas in a xenograft model of human fibrosarcoma cells, suggesting that at least in vitro, preadipocytes are not the only target cell of the chromosomal translocation t(12;16)(q13;p11) [19]. Interestingly, FUS-DDIT3 is not able to block adipogenesis in MEFs obtained from aP2-FUS-DDIT3 mice, which express FUS-DDIT3 under the control of the aP2 promoter, a downstream target of PPARgamma expressed in late stages of adipogenesis [20]. Further support to the idea that liposarcoma develops from uncommitted cells comes from the studies showing that the expression of FUS-DDIT3 in primary mesenchymal progenitor cells give rise to myxoid liposarcoma-like tumors [21], confirming that the cell type is critical for the oncogenic activity of FUS-DDIT3. In agreement with this view is the genomic analysis carried out in human myxoid liposarcoma [22], which is compatible with the genetic program of a primitive target cell from which myxoid liposarcoma could arise. Consistent with this notion, we reported the first in vivo evidence for a link between a chimeric protein generated by a chromosomal translocation and a human solid tumor by the generation of transgenic mice expressing FUS-DDIT3 transgene under the control of the ubiquitous E1Falpha promoter, which has found to be functional in mesenchymal progenitor/stem cells [21]. These FUS-DDIT3 transgenic mice developed liposarcomas that resemble their human counterpart [17]. Despite ubiquitously expression of FUS-DDIT3 oncogene, these mice exclusively developed liposarcomas, suggesting that FUS-DDIT3 may impose an adipocytic program with a partial developmental blockade in mesenchymal cell progenitors. The immature nature of liposarcoma cell progenitors was confirmed by the generation of aP2-FUS-DDIT3 transgenic mice, where FUS-DDIT3, expressed in adipocytes, but not in progenitor cells, is not able to induce liposarcoma development [20]. Moreover, mice expressing the altered form DDIT3-FUS, created by the in-frame fusion of the FUS domain to the carboxy end of DDIT3 also developed liposarcomas [18] indicating that the activity of the fusion protein FUS-DDIT3 is independent of the chimeric junction. By contrast, mice expressing high levels of DDIT3, which lacks the FUS domain, were not able to develop any tumor despite its tumorigenicity in vitro[19] although the co-expression of the FUS domain was able to restore liposarcoma development suggesting that it plays a critical role in the pathogenesis of liposarcoma [22]. Taken together, these data indicate that FUS-DDIT3-liposarcomas develop from uncommitted progenitor cells in which FUS-DDIT3 prevents the development of adipocytic precursors [23]-[24].
###end p 10
###begin p 11
###xml 187 191 183 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Rosen1">[25]</xref>
###xml 192 196 188 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Rosen3">[27]</xref>
###xml 852 856 825 829 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Rosen1">[25]</xref>
###xml 857 861 830 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Rosen3">[27]</xref>
###xml 1025 1033 982 990 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1033 1037 990 994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Lin1">[28]</xref>
###xml 1289 1293 1239 1243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Lin1">[28]</xref>
###xml 1294 1298 1244 1248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Calkhoven1">[30]</xref>
Previous studies have identified a number of transcription factors involved in adipocyte differentiation. These include PPARgamma and members of the C/EBP family of transcription factors [25]-[27]. Many of the components of the gene regulatory network that controls the differentiation of adipocytes have been elucidated in studies of cultured 3T3-L1 preadipocytes and MEFs. These transcription factors are expressed as a cascade in which C/EBPbeta and C/EBPdelta, expressed during the first stages of the adipocyte differentiation program, induce the expression of C/EBPalpha and PPARgamma, the master regulator of adipogenesis. A positive feedback loop mechanism between PPARgamma and C/EBPalpha enhances their activities. This transcriptional cascade finishes with the expression of markers of mature adipocytes such as ap2, adiponectin and adipsin [25]-[27]. There are two PPARgamma isoforms generated by alternative splicing, PPARgamma1 and PPARgamma2, being PPARgamma2 more efficient to induce terminal differentiation in vitro[28]. In an adipocytic context, the truncated isoforms of C/EBPbeta and C/EBPalpha (LIP and p30, respectively) have a negative effect on adipogenesis, while the full length isoforms (LAP and p42, respectively) enhance the adipocyte differentiation program [28]-[30].
###end p 11
###begin p 12
###xml 161 170 161 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUS-DDIT3</italic>
###xml 250 259 250 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUS-DDIT3</italic>
###xml 392 396 392 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-PrezMancera1">[24]</xref>
The fact that FUS-DDIT3-associated liposarcomas initiate in uncommitted progenitor cells and generate early adipocytic precursors indicate an important role for FUS-DDIT3 in the control of early adipocytic development. In this model, the presence of FUS-DDIT3 would prevent the development of the adipocytic precursors, leading to the observed buildup of the early precursors in liposarcomas [24]. However, little is known about the molecular mechanisms underlying this phenotype. Here, we have unmasked the molecular pathways preventing the development of the adipocytic precursors in liposarcomas induced by the expression of the fusion protein FUS-DDIT3. We demonstrate that FUS-DDIT3 interferes with the PPARgamma and C/EBPalpha activities. In addition, we show that the regulation of the translation machinery by FUS-DDIT3 plays an important role in the blockade of adipogenesis associated to liposarcoma development. The present study establishes for the first time the role of FUS-DDIT3 in preventing the development of adipocytic precursors in liposarcoma.
###end p 12
###begin title 13
Materials and Methods
###end title 13
###begin title 14
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice
###end title 14
###begin p 15
###xml 130 134 130 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-PerezLosada1">[17]</xref>
###xml 196 205 196 205 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUS-DDIT3</italic>
###xml 237 241 237 241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-PrezMancera2">[31]</xref>
###xml 242 246 242 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-PrezCaro1">[33]</xref>
###xml 305 308 305 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Not</italic>
###xml 94 98 <span type="species:ncbi:10090">mice</span>
###xml 155 159 <span type="species:ncbi:10090">mice</span>
###xml 190 195 <span type="species:ncbi:9606">human</span>
Animals were housed under non-sterile conditions in a conventional animal facility. FUS-DDIT3 mice have been previously described [17]. CombitTA-FUS-DDIT3 mice were generated by cloning the human FUS-DDIT3 cDNA into the Combi-tTA vector [31]-[33]. Linear DNA fragments for microinjection were obtained by NotI digestion and injected into CBAxC57BL/6J fertilized eggs. All experiments were done according to the relevant regulatory standards.
###end p 15
###begin title 16
Histological analysis
###end title 16
###begin p 17
###xml 423 427 <span type="species:ncbi:10090">mice</span>
Tumor samples were closely examined under the dissecting microscope and processed into paraffin, sectioned and examined histologically. All samples were taken from homogenous and viable portions of the resected sample by the pathologist and fixed within 2-5 min. of excision. Hematoxylin- and eosin-stained sections of each tissue were reviewed by a single pathologist (Teresa Flores). For comparative studies, age-matched mice were used.
###end p 17
###begin title 18
###xml 23 28 <span type="species:ncbi:10090">mouse</span>
Preparation of primary mouse embryonic fibroblasts (MEFs)
###end title 18
###begin p 19
###xml 96 100 96 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-PrezMancera4">[34]</xref>
Primary embryonic fibroblasts were harvested from 13.5 d.p.c. embryos and prepared as described [34]. Briefly, head and organs were removed; fetal tissue was rinsed in PBS, minced, and rinsed twice in PBS. Fetal tissue was treated with trypsin/EDTA and incubated for 30 min at 37 degreesC and subsequently dissociated in medium. After removal of large tissue clamps, the remaining cells were plated out in a 175 cm2 flask. After 48 h, confluent cultures were frozen down. These cells were considered as being passage 1 MEFs. For continuous culturing, MEF cultures were split 1:3. MEFs and the phiNX ecotropic packaging cell line were grown at 37 degreesC in Dubelcos-modified Eagle's medium (DMEM; Boehringer Ingelheim) supplemented with 10% heat-inactivated FBS (Boehringer Ingelheim). All the cells were negative for mycoplasma (MycoAlertTM Mycoplasma Detection Kit, Cambrex).
###end p 19
###begin title 20
Adipocyte differentiation
###end title 20
###begin p 21
###xml 254 255 247 248 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
Wild-type, FUS-DDIT3 and CombitTA-FUS-DDIT3 MEFs were cultured at 37degreesC in standard D-MEM:F12 medium (Gibco) supplemented with 10% heat-inactivated FBS (Hyclone), 100 units/ml penicillin (Biowhittaker), and 100 mug/ml streptomycin (Biowhittaker). 106 cells of each genotype were plated to 10 cm plastic dishes and propagated to confluence. Two days after confluence, the adipocyte differentiation program was induced by feeding the cells with standard medium supplemented with 0.5 mM 3-isobutyl-1-Methylxantine (Sigma), 1 muM dexamethasone (Sigma) and 5 mug/ml insulin (Sigma) for two days, and then, with standard medium supplemented with 5 mug/ml insulin for 6 days. This medium was renewed every two days. After 8 days, the appearance of cytoplasmic lipid accumulation was observed by Oil-Red-O staining. Briefly, cells were washed with phosphate-buffered saline (PBS), and then fixed with 3.7% formaldehyde for 2 minutes. After a wash with water, cells were stained with 60% filtered Oil-Red-O stock solution (0.5 g of Oil-Red-O (Sigma) in 100 ml of isopropanol) for 1 hour at room temperature. Finally, cells were washed twice in water and photographed. Lipid accumulation was defined as percentage of cells that are Oil-Red-O positive.
###end p 21
###begin title 22
RNA Extraction
###end title 22
###begin p 23
Total RNA from liposarcoma samples were isolated in two steps using TRIzol (Life Technologies, Inc., Grand Island, NY) followed by Rneasy Mini-Kit (Qiagen Inc., Valencia, CA) purification following the manufacturer's RNA Clean-up protocol with the optional Oncolumn Dnase treatment. Total RNA from liposarcoma cell lines was isolated using the Rneasy Mini-Kit (Qiagen Inc., Valencia, CA). The integrity and the quality of RNA were verified by electrophoresis and its concentration measured.
###end p 23
###begin title 24
Reverse Transcription-PCR (RT-PCR)
###end title 24
###begin p 25
###xml 25 34 25 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUS-DDIT3</italic>
###xml 445 472 443 470 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-GGTTATGGCAATCAAGACCAG-3&#8242;</named-content>
###xml 487 514 485 512 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-CTTGCAGGTCCTCATACCAGG-3&#8242;</named-content>
###xml 38 43 <span type="species:ncbi:9606">human</span>
###xml 97 102 <span type="species:ncbi:10090">mouse</span>
To analyze expression of FUS-DDIT3 in human liposarcoma cell lines, CombitTA-FUS-DDIT3 MEFs, and mouse liposarcomas, RT-PCR was performed according to the manufacturer's protocol in a 20-mul reaction containing 50 ng of random hexamers, 3 mug of total RNA, and 200 units of Superscript II RNase H- reverse transcriptase (GIBCO/ BRL). The sequences of the specific primers, which amplifiy specifically the fusion region, were as follows: FUS-F1: 5'-GGTTATGGCAATCAAGACCAG-3' and DDIT3-B1: 5'-CTTGCAGGTCCTCATACCAGG-3'. The thermocycling parameters for the polymerase chain reaction were as follows: 30 cycles at 94degreesC for 1 min, 60degreesC for 1 min and 72degreesC for 1 min. The PCR products were confirmed by hybridization with specific probes. Amplification of beta-actin served as a control to assess the quality of each RNA sample.
###end p 25
###begin title 26
Retroviral infection
###end title 26
###begin p 27
###xml 167 168 165 166 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 335 340 <span type="species:ncbi:10090">mouse</span>
###xml 356 359 <span type="species:ncbi:10116">rat</span>
FUS-DDIT3 MEFs were infected with high-titers retrovirus stocks produced by transient transfection of phiNX cells. The day before the infection, cells were plate at 106 cells per 10-cm dish. Infected MEFs were selected for 3 days with 2 mug/mL of puromycin (Sigma) and replated to carry out the adipocyte differentiation protocol. The mouse PPARgamma2 and rat C/EBPalpha cDNAs were subcloned in the pQCXIP retroviral vector (Clontech).
###end p 27
###begin title 28
Western blot analysis
###end title 28
###begin p 29
###xml 321 326 <span type="species:ncbi:9606">Human</span>
Whole-cell extracts of exponentially growing cells were prepared in lysis buffer (65 mM Tris pH7, 1% NP40, 2 mM EDTA, 100 mM NaCl) containing the complete cocktail of proteases inhibitors (Roche), and protein concentrations were determined with the Bradford assay reagent (Bio-Rad Laboratories, Inc., Melville, NY, USA). Human adipocyte extract was obtained from Zen-Bio (#TCE-A10-1). Western blot analysis of different cells and tissues were carried out using the Mini Tratans-Blot Cell system (BIO-RAD). Lysates were run on a 10% SDS-PAGE gel and transferred to a PVDF membrane. After blocking in 5% dry milk, the membrane was probed with the following primary antibodies: PPARgamma (H-100 and E-8, Santa Cruz Biotechnology), C/EBPbeta (C-19, Santa Cruz Biotechnology), C/EBPdelta (M-17, Santa Cruz Biotechnology), C/EBPalpha (14AA, Santa Cruz Biotechnology), FABP4 (aP2) (#10004944, Cayman Chemical), adiponectin (Chemicon International, #MAB3608), eIF2alpha (Cell Signaling#9722), eIF4E (Cell Signaling#9742) and actin (I-19, Santa Cruz Biotechnology). Reactive bands were detected with an ECL plus system (Amersham).
###end p 29
###begin title 30
Luciferase assays
###end title 30
###begin p 31
###xml 599 604 <span type="species:ncbi:9606">human</span>
###xml 869 875 <span type="species:ncbi:9913">bovine</span>
The reporter containing the proximal part of the hPPARgamma2 promoter cloned in front of the luciferase gene (pGL3-hPPARgamma2p1000 vector) was kindly provided by Dr. Johan Auwerx (35). The ratC/EBPalphawtpSG5 and ratC/EBPbetawtpSG5 expression vectors were kindly provided by Dr. Achim Leutz (25). The reporter containing the ratC/EBPalpha promoter (pCEBP1171) was kindly provided by Dr. Ana Perez-Castillo (36). The expression vectors pcDNA3-hFUS-DDIT3, BOS-hDDIT3 and pcDNA3-NH2-hFUS were generated by cloning the corresponding cDNAs into the expression plasmids. For reporter assays, U2OS cells (human bone osteosarcoma epithelial cells) were transfected using Dual-Luciferase (Promega) with normalization to Renilla luciferase, and mean+/-standard error was determined from at least three data points. U2OS cells were maintained in DMEM supplemented with 10% fetal bovine serum.
###end p 31
###begin title 32
CAT assays
###end title 32
###begin p 33
###xml 84 90 <span type="species:ncbi:10090">murine</span>
###xml 230 236 <span type="species:ncbi:9913">bovine</span>
The CAT reporter containing the approximately2.5 kb proximal promoter region of the murine eIF4E promoter, pm4ECAT, was kindly provided by Dr. Emmett V. Schmidt. C3H10T1/2 cells were maintained in DMEM supplemented with 10% fetal bovine serum. The transfections were carried out using the Profection Mammalia Transfection System Kit (PROMEGA). Cells were harvested approximately60 hr later and extracts were assayed for CAT activity. Relative CAT activities were determined by comparing the ratios of acetylated/unacetylated [14C]chloramphenicol present in spots cut from the thin-layer chromatographs. Equivalent amounts of protein (15-25 mg as determined with Bio-Rad protein kit) and a reaction time of 1 hr were used in all CAT assays, which kept all values within the linear range. Values (average of three independent experiments) show CAT activities relative to extracts of cells transfected with the CAT reporter alone set to a value of 1.
###end p 33
###begin title 34
Results
###end title 34
###begin title 35
###xml 67 82 <span type="species:ncbi:10090">transgenic mice</span>
Expression of adipogenic genes in liposarcomas arisen in FUS-DDIT3 transgenic mice
###end title 35
###begin p 36
###xml 182 186 182 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Rosen1">[25]</xref>
###xml 187 191 187 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Rosen3">[27]</xref>
###xml 308 317 308 317 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1A</bold>
###xml 308 317 308 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002569-g001"><bold>Figure 1A</bold></xref>
###xml 567 571 567 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-PerezLosada1">[17]</xref>
###xml 673 682 673 682 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1B</bold>
###xml 673 682 673 682 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002569-g001"><bold>Figure 1B</bold></xref>
###xml 1013 1022 994 1003 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1B</bold>
###xml 1013 1022 994 1003 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002569-g001"><bold>Figure 1B</bold></xref>
###xml 1087 1096 1068 1077 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1C</bold>
###xml 1087 1096 1068 1077 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002569-g001"><bold>Figure 1C</bold></xref>
###xml 1121 1130 1102 1111 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUS-DDIT3</italic>
###xml 1181 1190 1162 1171 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1D</bold>
###xml 1181 1190 1162 1171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002569-g001"><bold>Figure 1D</bold></xref>
###xml 1335 1344 1316 1325 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1B</bold>
###xml 1335 1344 1316 1325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002569-g001"><bold>Figure 1B</bold></xref>
###xml 1487 1491 1468 1472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Calkhoven1">[30]</xref>
###xml 551 566 <span type="species:ncbi:10090">transgenic mice</span>
The development of adipose tissue involves a differentiation switch that activates a new program of gene expression, followed by accumulation of lipids in a hormone-sensitive manner [25]-[27]. However, liposarcomas are characterized for the accumulation of committed adipocytic precursors named adipoblasts (Figure 1A). To explore the molecular basis through which FUS-DDIT3 impairs the normal adipocyte differentiation program, we examined the expression levels of the proteins responsible for normal adipogenesis in liposarcomas arisen in FUS-DDIT3 transgenic mice [17]. Fresh liposarcoma samples were lysed in NP40 lysis buffer and analyzed by western-blot. As shown in Figure 1B, the liposarcomas expressed high levels of C/EBPdelta and C/EBPbeta (LIP and LAP isoforms), which are expressed during the early stages of adipogenesis. On the contrary, liposarcomas expressed low levels of both the transcription factors involved in the late stages of adipogenesis, such as PPARgamma1, PPARgamma2 and C/EBPalpha (Figure 1B) and the mature adipocyte markers, such as ap2 and adiponectin (Figure 1C). The expression of the FUS-DDIT3 transgene in liposarcomas was assessed by RT-PCR (Figure 1D). Interestingly, we found that the truncated C/EBPalpha-p30 isoform was expressed at higher levels than the full length C/EBPalpha-p42 isoform (Figure 1B), which is congruent with a blockade in adipocyte differentiation and a transformed phenotype similar to that observed in preadipocyte 3T3-L1 [30]. Taken together, these results suggest that FUS-DDIT3 could prevent adipocytic precursors to differentiate by acting on transcription factors involved in both the early stages of adipogenesis and the late ones.
###end p 36
###begin title 37
###xml 56 71 <span type="species:ncbi:10090">transgenic mice</span>
###xml 79 84 <span type="species:ncbi:9606">human</span>
Adipogenic gene expression in liposarcomas of FUS-DDIT3 transgenic mice and in human liposarcoma cell lines carrying the translocation t(12;16)(q13;p11).
###end title 37
###begin p 38
###xml 1022 1031 1006 1015 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUS-DDIT3</italic>
###xml 189 194 <span type="species:ncbi:10090">mouse</span>
###xml 360 375 <span type="species:ncbi:10090">transgenic mice</span>
###xml 380 385 <span type="species:ncbi:9606">human</span>
###xml 832 847 <span type="species:ncbi:10090">transgenic mice</span>
###xml 855 860 <span type="species:ncbi:9606">human</span>
###xml 1016 1021 <span type="species:ncbi:9606">human</span>
###xml 1085 1100 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1108 1113 <span type="species:ncbi:9606">human</span>
(A) Hematoxylin/eosin stained sections showing the presence of lipoblasts with round nuclei and accumulation of intracellular lipid in a liposarcoma arisen in the chest region of FUS-DDIT3 mouse (10x and 40x magnifications are shown). (B) Western blot analyses of regulators of adipocyte function in white adipose tissue (WAT), liposarcoma arisen in FUS-DDIT3 transgenic mice and human liposarcomas cell lines expressing FUS-DDIT3 (LIS-3 and LIS-4). Cell and tissue extracts (10 mug) were resolved in SDS-PAGE gel (10% acrylamide), followed by immunoblotting analysis with anti-C/EBPbeta, anti-C/EBPdelta, anti-PPARgamma, anti-C/EBPalpha and anti-actin antibodies. These data are representative of three independent experiments. (C) Western blot analysis of fat cell markers such as aP2 and adiponectin in liposarcomas of FUS-DDIT3 transgenic mice and in human liposarcoma cell lines carrying the translocation t(12;16)(q13;p11). These data are representative of three independent experiments. (D) Expression of the human FUS-DDIT3 oncogene by RT-PCR both in liposarcomas of FUS-DDIT3 transgenic mice and in human liposarcoma cell lines carrying the translocation t(12;16)(q13;p11).
###end p 38
###begin title 39
###xml 70 75 <span type="species:ncbi:9606">human</span>
Expression pattern of transcription factors governing adipogenesis in human liposarcoma cells
###end title 39
###begin p 40
###xml 378 387 378 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUS-DDIT3</italic>
###xml 403 412 403 412 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1D</bold>
###xml 403 412 403 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002569-g001"><bold>Figure 1D</bold></xref>
###xml 646 657 646 657 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1B-C</bold>
###xml 646 657 646 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002569-g001"><bold>Figure 1B-C</bold></xref>
###xml 165 180 <span type="species:ncbi:10090">transgenic mice</span>
###xml 201 206 <span type="species:ncbi:9606">human</span>
###xml 281 286 <span type="species:ncbi:9606">human</span>
###xml 493 498 <span type="species:ncbi:9606">human</span>
###xml 629 644 <span type="species:ncbi:10090">transgenic mice</span>
###xml 733 738 <span type="species:ncbi:9606">human</span>
###xml 836 841 <span type="species:ncbi:10090">mouse</span>
###xml 848 853 <span type="species:ncbi:9606">human</span>
Next, we wanted to confirm that the characteristic expression pattern of transcription factors governing adipogenesis detected in liposarcomas coming from FUS-DDIT3 transgenic mice was also present in human liposarcoma cells. In order to address this aim, we took advantage of two human liposarcoma cell lines harboring the chromosomal translocation t(12;16) and expressing the FUS-DDIT3 chimeric gene (Figure 1D). The analysis of the expression pattern of these transcription factors in both human liposarcoma cell lines confirmed an expression pattern similar to that previously observed in liposarcomas derived from FUS-DDIT3 transgenic mice (Figure 1B-C), although we detected variable, although low, levels of PPARgamma1 in the human liposarcoma cell lines. These results demonstrate that tumors arisen in the FUS-DDIT3 transgenic mouse mimic human liposarcomas both histologically and molecularly. Taken together, these findings suggest that FUS-DDIT3 could prevent the development of committed adipocytic precursors in liposarcoma through the interference with PPARgamma and C/EBPalpha expression, two transcription factors with a critical role in adipogenesis.
###end p 40
###begin title 41
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
In vivo suppression of FUS-DDIT3 rescues the adipocyte differentiation block
###end title 41
###begin p 42
###xml 230 239 230 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUS-DDIT3</italic>
###xml 410 414 410 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-PrezMancera2">[31]</xref>
###xml 415 419 415 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-PrezCaro1">[33]</xref>
###xml 664 673 664 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUS-DDIT3</italic>
###xml 916 925 916 925 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2A</bold>
###xml 916 925 916 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002569-g002"><bold>Figure 2A</bold></xref>
###xml 1174 1183 1174 1183 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2B</bold>
###xml 1174 1183 1174 1183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002569-g002"><bold>Figure 2B</bold></xref>
###xml 1462 1471 1462 1471 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2B</bold>
###xml 1462 1471 1462 1471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002569-g002"><bold>Figure 2B</bold></xref>
###xml 1746 1755 1738 1747 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2C</bold>
###xml 1746 1755 1738 1747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002569-g002"><bold>Figure 2C</bold></xref>
###xml 159 174 <span type="species:ncbi:10090">transgenic mice</span>
###xml 769 773 <span type="species:ncbi:10090">mice</span>
###xml 1575 1579 <span type="species:ncbi:10090">mice</span>
The above results support the view that FUS-DDIT3 expression is enough to induce the adipocyte differentiation block. In order to determine this, we generated transgenic mice using the Combi-tTA system, in which the expression of FUS-DDIT3 gene could be exogenously regulated. This system, which has the transactivator and the tet-operator minimal promoter driving the expression gene unit on a single plasmid [31]-[33], ensures the integration of the transactivator and reporter gene units in equal copy numbers in a direct cis-configuration at the same chromosomal locus and prevents genetic segregation of the control elements during breeding. Insertion of the FUS-DDIT3 gene under the control of the tetO-minimal promoter yielded the plasmid CombitTA-FUS-DDIT3 and mice were generated. CombitTA-FUS-DDIT3 expression was determined in MEFs after culturing for two days in the presence or absence of tetracycline (Figure 2A). CombitTA-FUS-DDIT3 was detected in MEFs without tetracycline but not in cells cultured with tetracycline (20 ng/ml). To further examine the contribution of FUS-DDIT3 to adipogenesis, we isolated MEFs from days 13.5 of CombitTA-FUS-DDIT3 embryos (Figure 2B). At day 8 after hormonal induction, there is not lipid accumulation, defined as percentage of cells that are Oil-Red-O positive, in CombitTA-FUS-DDIT3 MEFs (1-3%). However, this differentiation block was reverted upon doxycycline treatment of CombitTA-FUS-DDIT3 MEFs (15-25%) (Figure 2B). Similarly, the impaired expression of PPARgamma and C/EBPalpha in liposarcomas of CombitTA-FUS-DDIT3 mice was normalized following administration of tetracycline (4 gr/L in the drinking water for 2 weeks, a dose sufficient to suppress of exogenous -FUS-DDIT3 expression) (Figure 2C). The demonstration that FUS-DDIT3 downregulation was sufficient to normalize the adipocyte differentiation capacity of FUS-DDIT3 cells further indicates that PPARgamma2 and C/EBPalpha were regulated directly by FUS-DDIT3.
###end p 42
###begin title 43
CombitTA-FUS-DDIT3 expression and effect of FUS-DDIT3 on adipocyte differentiaton.
###end title 43
###begin p 44
###xml 1019 1023 <span type="species:ncbi:10090">mice</span>
A) Analysis of the tetracycline (Doxycycline) dependent CombitTA-FUS-DDIT3 expression by RT-PCR in the presence (+tet) or in the absence (-tet) of doxycycline in MEF (the time of treatment with doxycycline was 48 hours). Actin was used to check the RNA integrity and loading. B) Adipocyte differentiation in CombitTA-FUS-DDIT3 MEFs after suppression of FUS-DDIT3 expression by tetracycline treatment. CombitTA-FUS-DDIT3 MEFs in the presence (+tet) or in the absence (-tet) of doxycycline were cultered up to confluence and grown in the presence of standard adipose differentiation induction medium. At day 8 after induction of adipocyte differentiation, cells were fixed and stained for neutral lipids with Oil-Red-O and the morphological differentiation is shown (the original magnification is x20). This experiment was repeated three times using cells prepared from different embryos and similar results were obtained. C) Western blot analyses of PPARgamma, and C/EBPalpha in liposarcoma arisen in CombitTA-FUS-DDIT3 mice in the presence (+tet) or in the absence (-tet) of doxycycline. Doxycycline was given at 4 mg/mL for 4 weeks.
###end p 44
###begin title 45
The adipogenesis defects in FUS-DDIT3 MEFs can be rescued by ectopic expression of PPARgamma2
###end title 45
###begin p 46
###xml 374 382 362 370 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3</bold>
###xml 374 382 362 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002569-g003"><bold>Figure 3</bold></xref>
###xml 510 514 498 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-PrezMancera4">[34]</xref>
###xml 516 520 504 508 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Fajas1">[35]</xref>
###xml 820 829 804 813 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3A</bold>
###xml 820 829 804 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002569-g003"><bold>Figure 3A</bold></xref>
###xml 990 999 970 979 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3A</bold>
###xml 990 999 970 979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002569-g003"><bold>Figure 3A</bold></xref>
Our data revealed that PPARgamma2 expression is modulated by FUS-DDIT3, suggesting an interesting link between this gene and FUS-DDIT3. In order to confirm this transcriptional regulation we re-introduced PPARgamma2 in both control and FUS-DDIT3 MEFs by retroviral transduction and evaluated the adipogenesis capacity and the expression level of PPARgamma2 by western-blot (Figure 3). The adipogenesis of MEFs by hormonal induction is a well established model system for the study of adipocyte differentiation [34], [35]. To further examine the contribution of PPARgamma2 to FUS-DDIT3-mediated adipogenesis, we isolated MEFs from days 13.5 of FUS-DDIT3 and control embryos. At day 8 after hormonal induction, there is lipid accumulation in control MEFs (20-35%) and this lipid accumulation is lacking in FUS-DDIT3 MEFs (Figure 3A). However, retrovirus-mediated expression of PPARgamma2 in FUS-DDIT3-MEFS re-established the adipocyte differentiation capacity to wild-type levels as shown in Figure 3A. The demonstration that PPARgamma2 was sufficient to normalize the adipocyte differentiation capacity of FUS-DDIT3 cells further indicates that PPARgamma2 was regulated directly by FUS-DDIT3 and it plays a critical role in the blockade of the adipocyte differentiation of FUS-DDIT3 adipocytic precursors.
###end p 46
###begin title 47
Retroviral-mediated expression of PPARgamma2 rescues the impaired adipogenesis of FUS-DDIT3 MEFs.
###end title 47
###begin p 48
A) FUS-DDIT3 MEFs were infected with either control retroviral vector or one expressing PPARgamma2 (pQCXIP-PPARgamma2) and selected for 3 days with 2 mug/ml puromycin. Then, wild-type MEF, FUS-DDIT3 MEF and PPARgamma2 expressing FUS-DDIT3-MEF were cultered up to confluence and grown in the presence of standard adipose differentiation induction medium. At day 8 after induction of adipocyte differentiation, cells were fixed and stained for neutral lipids with Oil-Red-O and the morphological differentiation is shown (the original magnification is x20). This experiment was repeated three times using cells prepared from all lines and from different embryos and similar results were obtained. B) Analysis of the PPARgamma2 protein by western-blot in FUS-DDIT3 MEFs infected with either a control retroviral vector (pQCXIP) or one expressing PPARgamma2 (pQCXIP- PPARgamma2) 4 days after infection.
###end p 48
###begin title 49
FUS-DDIT3 represses the PPARgamma2 promoter
###end title 49
###begin p 50
###xml 40 49 40 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUS-DDIT3</italic>
###xml 338 342 322 326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-PrezMancera4">[34]</xref>
###xml 344 348 328 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Fajas1">[35]</xref>
###xml 434 442 415 423 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4</bold>
###xml 434 442 415 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002569-g004"><bold>Figure 4</bold></xref>
###xml 604 613 581 590 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUS-DDIT3</italic>
###xml 806 815 772 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUS-DDIT3</italic>
###xml 847 855 813 821 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4</bold>
###xml 847 855 813 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002569-g004"><bold>Figure 4</bold></xref>
###xml 227 232 <span type="species:ncbi:9606">human</span>
Because the results so far suggest that FUS-DDIT3directly regulates PPARgamma2 expression, we examined whether FUS-DDIT3 might be directly involved in the control of PPARgamma2 transcription. A 1 kb proximal promoter region of human PPARgamma2 was previously shown to be sufficient to drive the PPARgamma2's expression in reporter assays [34], [35] and it is active in U2OS cells when co-transfected with C/EBPbeta expression vector (Figure 4). To directly assess the ability of FUS-DDIT3 to activate transcription from DNA sequences present in the PPARgamma2 promoter, an expression vector containing a FUS-DDIT3 cDNA was co-transfected into U2OS cells along with the reporter vector containing the PPARgamma2 promoter (pGL3-hPPARgamma2p1000 vector) and with C/EBPbeta expression vector. Co-expression of FUS-DDIT3 repressed luciferase activity (Figure 4).
###end p 50
###begin title 51
FUS-DDIT3 represses the PPARgamma2 promoter.
###end title 51
###begin p 52
###xml 415 424 400 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUS-DDIT3</italic>
###xml 740 746 711 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PPARg2</italic>
###xml 35 40 <span type="species:ncbi:9606">human</span>
###xml 409 414 <span type="species:ncbi:9606">human</span>
###xml 435 440 <span type="species:ncbi:9606">human</span>
###xml 461 466 <span type="species:ncbi:9606">human</span>
###xml 734 739 <span type="species:ncbi:9606">human</span>
###xml 812 816 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
A 1 kb proximal promoter region of human PPARgamma2 was previously shown to be sufficient to drive the PPARgamma2's expression in reporter assays [34. 35] and it is active in U2OS cells when co-transfected with C/EBPbeta expression vectors. To directly assess the ability of FUS-DDIT3 to modulate transcription from DNA sequences present in the PPARgamma2 promoter, an expression vector containing either the human FUS-DDIT3 cDNA, the human DDIT3 domain or the human FUS domain were co-transfected into U2OS cells along with the reporter vector containing the PPARgamma2 promoter (pGL3-hPPARgamma2p1000 vector) and C/EBPbeta expression vector (ratC/EBPbeta wtpSG5). Luciferase reporter assays demonstrate that FUS-DDIT3 repressed the human PPARg2 reporter in a DDIT3.dependent manner. In all lines, 1 mug of pRL-SV40 (Renilla basal control (PROMEGA) was used for normalization of the results along with 5 mug of pGL3-hPPARgamma2p1000 (lines 2-10); 3 mug of ratC/EBPbeta wtpSG5 (lines 3-10); 3, 5 and 7 mug of the hFUS-DDIT3 expression vector (lines 4-6, respectively); 3 and 7 mug of the hDDIT3 expression vector (lines 7-8, respectively); 3 and 7 mug the NH2-hFUS expression vector (lines 9-10, respectively); 5 mug of the hFUS-DDIT3 expression vector (line 11). These data are representative of three independent experiments.
###end p 52
###begin p 53
###xml 162 166 162 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-PerezLosada2">[18]</xref>
###xml 731 739 710 718 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4</bold>
###xml 731 739 710 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002569-g004"><bold>Figure 4</bold></xref>
###xml 890 894 866 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Adelmant1">[14]</xref>
Previous results have provided evidence that both the FUS and the DDIT3 domains of FUS-DDIT3 play a specific and critical role in the pathogenesis of liposarcoma [18]. Thus, we next investigated which FUS-DDIT3 domain was responsible for the repression of the PPARgamma2 promoter. Using the same system, we showed that while the co-expression of the domain NH2-FUS did not produce any effect on the transactivation capability of C/EBPbeta, the co-expression of the DDIT3 domain produced a dramatic repression in the activation of the PPARgamma2 promoter by C/EBPbeta, indicating that the DDIT3 domain of FUS-DDIT3 was involved in the repression of the PPARgamma activity in liposarcomas by interfering with the C/EBPbeta activity (Figure 4). FUS-DDIT3 might be inhibiting this C/EBPbeta transcriptional activity by forming heterodimer as it has been previously shown in NIH-3T3 fibroblasts [14].
###end p 53
###begin title 54
C/EBPalpha cannot rescue the impaired adipogenesis of FUS-DDIT3 MEFs
###end title 54
###begin p 55
###xml 176 185 172 181 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1B</bold>
###xml 176 185 172 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002569-g001"><bold>Figure 1B</bold></xref>
###xml 423 432 415 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUS-DDIT3</italic>
###xml 725 729 705 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-MenendezHurtado1">[36]</xref>
###xml 839 843 815 819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-MenendezHurtado1">[36]</xref>
###xml 929 938 902 911 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5A</bold>
###xml 929 938 902 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002569-g005"><bold>Figure 5A</bold></xref>
###xml 1100 1109 1069 1078 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUS-DDIT3</italic>
###xml 1283 1292 1245 1254 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUS-DDIT3</italic>
###xml 1324 1333 1286 1295 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5A</bold>
###xml 1324 1333 1286 1295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002569-g005"><bold>Figure 5A</bold></xref>
###xml 249 264 <span type="species:ncbi:10090">transgenic mice</span>
###xml 279 285 <span type="species:ncbi:9606">humans</span>
###xml 693 696 <span type="species:ncbi:10116">rat</span>
To further define the molecular mechanism by which FUS-DDIT3 alters the adipogenic potential of MEF, we next addressed how FUS-DDIT3 regulates the expression of C/EBPalpha. In Figure 1B we have previously shown that liposarcomas arisen in FUS-DDIT3 transgenic mice, similarly to humans, expressed lower levels of C/EBPalpha than wild type WAT, which is associated with an immature phenotype. This observation suggests that FUS-DDIT3 regulates C/EBPalpha expression. In order to examine whether FUS-DDIT3 might be directly involved in the control of C/EBPalpha transcription, we carried out reporter gene assays using a luciferase reporter gene containing 1171 bp of the promoter region of the rat C/EBPalpha gene (pCEBP1171) [36]. This reporter was previously shown to be sufficient to drive the C/EBPalpha's expression in reporter assays [36] and it is active in U2OS cells when co-transfected with C/EBPbeta expression vector (Figure 5A). To directly assess the ability of FUS-DDIT3 to activate transcription from DNA sequences present in the C/EBPalpha promoter, an expression vector containing a FUS-DDIT3 cDNA was co-transfected into U2OS cells along with the reporter vector containing the C/EBPalpha promoter (pCEBP1171) and with C/EBPbeta expression vector. Co-expression of FUS-DDIT3 repressed luciferase activity (Figure 5A). Therefore, FUS-DDIT3 is also the primary responsible for the transcriptional down-regulation of C/EBPalpha by interfering with C/EBPbeta activity.
###end p 55
###begin title 56
C/EBPalpha does not bypass adipogenesis blockade in FUS-DDIT3 expressing-MEF.
###end title 56
###begin p 57
###xml 125 129 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 257 260 <span type="species:ncbi:10116">rat</span>
(A) FUS-DDIT3 represses the C/EBPalpha transactivation induced by C/EBPbeta. U2OS cells were cotransfected with 1 mug of pRL-SV40 (Renilla basal control (PROMEGA), lines 1-6) along with: 5 mug of pCEBP1171 (luciferase reporter vector containing 1171 of the rat C/EBPalpha promoter, samples 2-6); 3 mug ratC/EBPbetawtpSG5 (C/EBPbeta expressing vector, lines 3-6); 3, 5 and 7 mug pcDNA3-hFUS-DDIT3 (hFUS-DDIT3 expression vector, lines 4-6); 5 mug of the hFUS-DDIT3 expression vector (line 7). These data are representative of three independent experiments. (B) Retroviral expression of C/EBPalpha does not rescue the adipocyte differentiation blockade in FUS-DDIT3 MEFs. FUS-DDIT3 MEFs were infected with a retroviral vector expressing C/EBPalpha (pQCXIP-C/EBPalpha) and selected for 3 days with 2 mug/ml puromycin. Then, wild-type MEF, FUS-DDIT3 MEF and C/EBPalpha expressing FUS-DDIT3-MEFS were cultered up to confluence and grown in the presence of standard adipose differentiation induction medium. At day 8 after induction of adipocyte differentiation, cells were fixed and stained for neutral lipids with Oil-Red-O and the morphological differentiation is shown (the original magnification is x20). This experiment was repeated three times using cells prepared from all lines and from different embryos and similar results were obtained. (C) Analysis of C/EBPalpha (p42-C/EBPalpha and p30-C/EBPalpha isoforms) protein expression by western-blot in FUS-DDIT3 MEFs infected with either a control retroviral vector (pQCXIP) or one expressing C/EBPalpha (pQCXIP- C/EBPalpha) 4 days after infection.
###end p 57
###begin p 58
###xml 143 147 135 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Rosen4">[37]</xref>
###xml 241 245 225 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Wu1">[38]</xref>
###xml 349 358 329 338 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3A</bold>
###xml 349 358 329 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002569-g003"><bold>Figure 3A</bold></xref>
###xml 662 671 626 635 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1B</bold>
###xml 662 671 626 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002569-g001"><bold>Figure 1B</bold></xref>
###xml 1259 1268 1203 1212 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5B</bold>
###xml 1259 1268 1203 1212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002569-g005"><bold>Figure 5B</bold></xref>
###xml 1365 1374 1305 1314 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5C</bold>
###xml 1365 1374 1305 1314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002569-g005"><bold>Figure 5C</bold></xref>
However, it has been previously reported that ectopic expression of C/EBPalpha is unable to induce adipogenesis in a PPARgamma null background [37], although in contrast, PPARgamma restores adipocitic potential in C/EBPalpha null fibroblast [38]. We have shown that PPARgamma2 induces terminal adipocyte differentiation in FUS-DDIT3 expressing MEF (Figure 3A). Thus and with the aim of clarifying the relationship between the PPARgamma and C/EBPalpha pathways in liposarcomas, we next assessed the role of the C/EBPalpha downregulation in the process of adipogenesis in FUS-DDIT3 MEFs, as these MEFs show a dramatic downregulation and inactivation of PPARgamma (Figure 1B). We investigated whether C/EBPalpha was also able to overcome the blockade in adipocyte differentiation shown by FUS-DDIT3-MEF. FUS-DDIT3 MEFs were infected with a retroviral vector expressing C/EBPalpha. To define whether overexpression of C/EBPalpha could rescue adipogenesis in FUS-DDIT3 cells, adipocytic differentiation was induced in FUS-DDIT3 MEFs infected either with empty vector or with the C/EBPalpha expressing vector. Of interest, the impaired adipocyte differentiation block in FUS-DDIT3 MEFs was not normalized by restoring C/EBPalpha at day 8 after hormonal induction, (Figure 5B), although the retroviral vector was producing C/EBPalpha correctly as defined by western-blot (Figure 5C).
###end p 58
###begin title 59
FUS-DDIT3 up-regulates expression of eIF4E in liposarcomas
###end title 59
###begin p 60
###xml 282 291 274 283 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1B</bold>
###xml 282 291 274 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002569-g001"><bold>Figure 1B</bold></xref>
###xml 715 719 700 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Calkhoven1">[30]</xref>
###xml 1015 1024 996 1005 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6A</bold>
###xml 1015 1024 996 1005 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002569-g006"><bold>Figure 6A</bold></xref>
###xml 1314 1323 1291 1300 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6A</bold>
###xml 1314 1323 1291 1300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002569-g006"><bold>Figure 6A</bold></xref>
###xml 226 231 <span type="species:ncbi:10090">mouse</span>
###xml 252 257 <span type="species:ncbi:9606">human</span>
###xml 955 959 <span type="species:ncbi:10090">mice</span>
###xml 964 969 <span type="species:ncbi:9606">human</span>
###xml 1209 1213 <span type="species:ncbi:10090">mice</span>
###xml 1520 1535 <span type="species:ncbi:10090">transgenic mice</span>
Although the inactivation of C/EBPalpha is not required, itself, for the blockade of adipogenesis in mesenchymal progenitor cells by FUS-DDIT3, however, the C/EBPalpha isoform ratio shift towards the truncated isoform both in mouse liposarcomas and in human liposarcoma cell lines (Figure 1B). It has been previously reported that the control of initiation of translation of C/EBPalpha and C/EBPbeta by the eukaryotic translation initiation factors eIF2 and eIF4E is critical for the behavior of preadipocytes 3T3-L1. Thus, high levels of the eukaryotic translation initiation factors produce a shift towards truncated C/EBP isoforms that, in turn, induce a blockade in the terminal differentiation of 3T3-L1 cells [30]. Thus, we next studied the expression level of eIF2alpha and eIF4E in FUS-DDIT3-liposarcomas. Analysis by western-blot of protein lysates showed a dramatic overexpression of both eIF4E and eIF2 in liposarcomas arisen both in FUS-DDIT3 mice and human liposarcomas cell lines FUS-DDIT3 positives (Figure 6A), explaining the shift towards the truncated p30 isoform of C/EBPalpha in liposarcomas. Similarly, the impaired expression of both eIF4E and eIF2 in liposarcomas of CombitTA-FUS-DDIT3 mice was normalized following administration of tetracycline (4 gr/L in the drinking water for 2 weeks) (Figure 6A), indicating that the fusion protein is directly responsible for the overexpression of both eIF4E and eIF2 in liposarcoma. Moreover, eIF4E was also strongly upregulated in normal WAT of FUS-DDIT3 transgenic mice, suggesting that overexpression of eIF4E may be one of the first events in the initiation of liposarcomas.
###end p 60
###begin title 61
FUS-DDIT3 upregulates eIF2alpha and eIF4E.
###end title 61
###begin p 62
###xml 136 140 <span type="species:ncbi:10090">mice</span>
###xml 176 180 <span type="species:ncbi:10090">mice</span>
###xml 191 196 <span type="species:ncbi:9606">human</span>
###xml 261 266 <span type="species:ncbi:9606">human</span>
###xml 340 344 <span type="species:ncbi:10090">mice</span>
###xml 689 694 <span type="species:ncbi:10090">mouse</span>
###xml 852 857 <span type="species:ncbi:10090">mouse</span>
###xml 1304 1309 <span type="species:ncbi:10090">mouse</span>
(A) Western blot analyses of eIF4E and eIF2alpha expression in wild-type white adipose tissue (WT-WAT), liposarcoma arisen in FUS-DDIT3 mice (Tumor), normal WAT from FUS-DDIT3 mice (FD-WAT), human liposarcomas cell lines expressing FUS-DDIT3 (LIS-3 and LIS-4), human adipose cells (Zen-bio), and in liposarcoma arisen in CombitTA-FUS-DDIT3 mice in the presence (+tet) or in the absence (-tet) of doxycycline (doxycycline was given at 4 mg/mL for 4 weeks). Cell and tissue extract (10 mug) were resolved in SDS-PAGE gel (10% acrylamide), followed by immunoblotting analysis with anti- eIF4E, anti- eIF2alpha and anti-actin antibodies. (B) Transactivation of the CAT reporter gene linked to mouse eIF4E promoter by FUS-DDIT3. C3H10T1/2 cells were transiently cotransfected with 1 mug of pm4ECAT (CAT reporter vector containing approximately2.5 kb of the mouse eIF4E promoter) together with 5 mug of pcDNA (empty vector, panel 2) or with 5 mug of pcDNA3-hFUS-DDIT3 (hFUS-DDIT3 expression vector, panel 3). The data represent the fold activation with respect to a sample where reporter alone was transfected (panel 1). Data represent an average obtained from three separated experiments. A representative thin layer chromatograph is shown on the right. (C) Transactivation of the CAT reporter gene linked to mouse eIF4E promoter by FUS and DDIT3 domains of FUS-DDIT3 fusion protein. C3H10T1/2 cells were transiently cotransfected with 1 mug of pm4ECAT together with 5 mug of a vector expressing the FUS domain (panel 2) or with 5 mug of a vector expressing the DDIT3 domain (panel 3). The data represent the fold activation with respect to a sample where reporter alone was transfected (panel 1). Data represent an average obtained from three separated experiments.
###end p 62
###begin p 63
###xml 342 346 342 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-TsukiyamaKohara1">[39]</xref>
###xml 633 637 621 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Lynch1">[40]</xref>
###xml 841 850 829 838 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6B</bold>
###xml 841 850 829 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002569-g006"><bold>Figure 6B</bold></xref>
###xml 213 217 <span type="species:ncbi:10090">mice</span>
###xml 601 607 <span type="species:ncbi:10090">murine</span>
Next, we examined whether this upregulation of eIF4E was a direct effect of FUS-DDIT3, or a consequence of the blockade in adipocyte differentiation in liposarcomas, as it has been previously shown that knock out mice for 4E-BP1, a protein that represses cap-dependent translation initiation by sequestering eIF4E, evidenced reduced WAT mass [39]. We examined whether FUS-DDIT3 might be directly involved in the control of the eIF4E expression. In order to address this question, we used a vector containing a CAT gene reporter under the control of approximately2.5 kb proximal promoter region of the murine eIF4E promoter (pm4ECAT) [40]. When U2OS cells were co-transfected with the reported vector along with the FUS-DDIT3 expression vector, there was a specific increae of the CAT activity compared to the activity with the empty vector (Figure 6B), demonstrating that FUS-DDIT3 is involved in the upregulation of eIF4E in liposarcomas.
###end p 63
###begin p 64
###xml 299 308 299 308 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6C</bold>
###xml 299 308 299 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002569-g006"><bold>Figure 6C</bold></xref>
We further investigated which FUS-DDIT3 domain was responsible for the repression of the eIF4E promoter. Using the same system, we proved that neither the co-expression of the domain NH2-FUS nor the co-expression of the DDIT3 domain produced any effect on the transactivation of the eIF4E promoter (Figure 6C), indicating that both domains are required for affecting eIF4E expression. These observations establish for the first time the role of FUS-DDIT3 in preventing the development of adipocytic precursors in liposarcoma development.
###end p 64
###begin title 65
Discussion
###end title 65
###begin p 66
###xml 178 187 178 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUS-DDIT3</italic>
###xml 235 251 235 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-PrezMancera1">[reviewed in 24]</xref>
Current studies support that FUS-DDIT3-associated liposarcomas initiate in uncommitted progenitor cells and generate early adipocytic precursors indicating an important role for FUS-DDIT3 in the control of early adipocytic development [reviewed in 24]. However, the molecular mechanisms used by FUS-DDIT3 to prevent the development of the adipocytic precursors, leading to the observed buildup of the early precursors in liposarcomas, remain mainly unknown. Here, we have attempted to rigorously unmask the molecular mechanisms associated with this blockade in adipocyte differentiation program of mesenchymal progenitor cells in myxoid liposarcomas harbouring the chromosomal translocation t(12;16)(q13;p11).
###end p 66
###begin p 67
###xml 332 341 320 329 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1A</bold>
###xml 332 341 320 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002569-g001"><bold>Figure 1A</bold></xref>
###xml 474 483 455 464 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1A</bold>
###xml 474 483 455 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002569-g001"><bold>Figure 1A</bold></xref>
###xml 649 658 622 631 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figures 4</bold>
###xml 649 658 622 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002569-g004"><bold>Figures 4</bold></xref>
###xml 658 663 631 636 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"> and </bold>
###xml 663 665 636 638 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5A</bold>
###xml 663 665 636 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002569-g005"><bold>5A</bold></xref>
###xml 836 845 809 818 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1C</bold>
###xml 836 845 809 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002569-g001"><bold>Figure 1C</bold></xref>
###xml 1069 1078 1042 1051 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUS-DDIT3</italic>
###xml 1396 1405 1369 1378 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUS-DDIT3</italic>
###xml 1565 1573 1530 1538 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 7</bold>
###xml 1565 1573 1530 1538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002569-g007"><bold>Figure 7</bold></xref>
###xml 1721 1725 1686 1690 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p190</sup>
###xml 1725 1729 1690 1694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Castellanos1">[41]</xref>
###xml 1747 1751 1708 1712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Altabef1">[42]</xref>
###xml 141 156 <span type="species:ncbi:10090">transgenic mice</span>
###xml 738 753 <span type="species:ncbi:10090">transgenic mice</span>
###xml 961 976 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1014 1019 <span type="species:ncbi:9606">human</span>
###xml 1268 1273 <span type="species:ncbi:10090">mouse</span>
###xml 1306 1311 <span type="species:ncbi:9606">human</span>
The analysis of the components of the gene regulatory network that controls adipocyte differentiation in liposarcomas developed in FUS-DDIT3 transgenic mice showed a dramatic decreased in the expression levels of the transcription factors involved in the final stages of adipogenesis, such as PPARgamma1, PPARgamma2 and C/EBPalpha (Figure 1A), while the expression levels of C/EBPdelta and C/EBPbeta, involved in early stages of adipocyte differentiation, were upregulated (Figure 1A). Moreover, we have shown that FUS-DDIT3 interferes with the PPARgamma2 and C/EBPalpha activities at a transcriptional level by repressing their promoter sequences (Figures 4 and 5A). In agreement with these findings, liposarcomas developed in FUS-DDIT3 transgenic mice also express mature adipocyte markers, such as ap2 or adiponectin, at low levels (Figure 1C). These molecular findings corroborate the accumulation of early precursors in liposarcomas developed in FUS-DDIT3 transgenic mice. Interestingly, LIS-3 and LIS-4, two human cells lines derived from liposarcomas expressing FUS-DDIT3, showed an almost identical pattern of expression of the components of the gene regulatory network that controls adipocyte differentiation, indicating further that the FUS-DDIT3 transgenic mouse model reproduces accurately the human pathology. Taken together these results strongly support that the expression of the FUS-DDIT3 oncogene is able to block the adipocyte differentiation program of target mesenchymal progenitor cells interacting with the PPARgamma and C/EBPalpha pathways (Figure 7) and contributing to generate a transformed phenotype, similarly to other fusion oncogenes associated to hematopoietic malignances, such as BCR-ABLp190[41] and PML-RARalpha [42].
###end p 67
###begin title 68
###xml 59 68 59 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUS-DDIT3</italic>
Model for the adipocyte differentiation arrest produced by FUS-DDIT3 in liposarcoma development.
###end title 68
###begin p 69
(A) Scheme of the normal differentiation program in mesenchymal progenitor cells. (B) FUS-DDIT3 blocks the adipocyte differentiation program in mesenchymal cell progenitors by interfering with the PPARgamma and C/EBPalpha activities at the transcriptional level. In addition, FUS-DDIT3 induces the expression of eIF4E, that in turns, is able to inactivate the C/EBPalpha pathway by shifting the normal isoform ratio towards the truncated p30- C/EBPalpha isoform, which has a negative effect on adipogenesis.
###end p 69
###begin p 70
###xml 79 83 71 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Rosen1">[25]</xref>
###xml 84 88 76 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Rosen3">[27]</xref>
###xml 312 316 288 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Rosen4">[37]</xref>
###xml 717 721 669 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Ren1">[43]</xref>
###xml 840 844 784 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Wu1">[38]</xref>
###xml 980 989 920 929 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FUS-DDIT3</italic>
###xml 1444 1452 1372 1380 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1507 1511 1435 1439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Batchvarova1">[15]</xref>
###xml 1591 1595 1519 1523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Engstrom1">[19]</xref>
###xml 1690 1694 1618 1622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-PerezLosada2">[18]</xref>
###xml 1711 1718 1639 1646 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1862 1866 1790 1794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-PrezMancera1">[24]</xref>
###xml 1650 1655 <span type="species:ncbi:10090">mouse</span>
C/EBPalpha and PPARgamma are key players in terminal adipocyte differentiation [25]-[27], although both transcription factors have different roles. Thus, while PPARgamma is able to induce terminal differentiation in a C/EBPalpha null background, C/EBPalpha has no ability to do it in a PPARgamma null fibroblast [37], suggesting that PPARgamma is the most important transcription factor involved in adipogenesis. Moreover, PPARgamma2, which contains an additional 31 amino acids at its amino terminal domain than PPARgamma1, has been shown to be the only PPARgamma isoform that is able to induce adipogenesis in 3T3-L1 preadipocytes in which PPARgamma1 and PPARgamma2 were repressed by zinc finger repressor proteins [43]. Moreover, it has been reported that C/EBPalpha may be required to maintain the expression on PPARgamma in adipocytes [38]. Here we have shown that while ectopic expression of PPARgamma2 is able to induce final adipogenesis of primary fibroblasts expressing FUS-DDIT3, C/EBPalpha is unable to rescue the impaired adipogenesis of adipocytic precursors expressing FUS-DDIT3, suggesting that the down-regulation of PPARgamma2 by FUS-DDIT3 is one of the critical steps in the blockade of adipocyte differentiation in liposarcomas. In addition, we show that the carboxy terminal domain of the fusion protein FUS-DDIT3 is the part of the protein involved in the represion of the PPARgamma2 promoter, which is congruent with the in vitro role of DDIT3 in adipocyte inhibition of 3T3-L1 cells [15] and liposarcoma development in a model using the HT1080 fibrosarcoma cell line [19]. However, ectopic expression of DDIT3 in a transgenic mouse model did not develop liposarcoma [18] indicating that in vivo the cellular environment and the cooperation of both domains of the chimeric protein FUS-DDIT3 play a critical role to induce frank malignancy [24].
###end p 70
###begin p 71
###xml 221 225 214 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Calkhoven1">[30]</xref>
###xml 658 662 630 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Goransson2">[44]</xref>
###xml 797 801 761 765 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Wu1">[38]</xref>
###xml 966 970 926 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Calkhoven1">[30]</xref>
###xml 1622 1638 1582 1598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0002569-Graff1">[reviewed in 45]</xref>
###xml 1538 1543 <span type="species:ncbi:9606">human</span>
###xml 1729 1744 <span type="species:ncbi:10090">transgenic mice</span>
The control of the translation initiation of C/EBPbeta and C/EBPalpha mRNAs has been shown to be important in the activity of both transcription factors, as truncated isoforms of them have negative effect on adipogenesis [30]. We also analyzed the ratio of C/EBPbeta and C/EBPalpha isoform expression in liposarcomas and proved that only C/EBPalpha had a shift towards the truncated isoforms, suggesting that while C/EBPalpha showed a reduced activity, C/EBPbeta had apparently a potential normal activity in liposarcomas. This could be unexpected, but the C/EBPbeta activity has been shown to be important in the FUS-DDIT3-mediated interleukin-6 expression [44]. These results suggest FUS-DDIT3 was also interfering with C/EBPalpha, required to maintain the expression on PPARgamma in adipocytes [38]. Interestingly, we found high levels of eIF4E and eIF2alpha in liposarcomas, two translation initiation factors involved in controlling the ratio of C/EBP isoforms [30]. Moreover, FUS-DDIT3 is able to transactivate the eIF4E promoter suggesting that FUS-DDIT3 is able to interfere with the translational initiation machinery and disrupt the normal adipocyte differentiation program of adipocyte progenitor cells in liposarcomas. The observation that both domains of FUS-DDIT3 are required to regulate eIF4E expression provides the first molecular evidence that the FUS component of the fusion protein is required not only for transformation but also influences the phenotype of the tumor cells. The eIF4E is frequently overexpressed in human cancers in relation to disease progression and drives cellular transformation [reviewed in 45]. In this sense, eIF4E was also strongly upregulated in normal adipose tissue of FUS-DDIT3 transgenic mice, suggesting that overexpression of eIF4E may be one of the primary events in the initiation of liposarcomas.
###end p 71
###begin p 72
###xml 950 958 922 930 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 7</bold>
###xml 950 958 922 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0002569-g007"><bold>Figure 7</bold></xref>
###xml 1057 1062 <span type="species:ncbi:9606">human</span>
In conclusion, we demonstrate that FUS-DDIT3 is able, itself, to impede the normal adipogenesis in mesenchymal progenitor cell contributing to achieve a transformed phenotype by blocking the adipocyte differentiation program. In order to achieve this, FUS-DDIT3 blocks the activity of the most vital adipogenic transcription factors: C/EBPalpha and PPARgamma. In addition, we show that this blockade is produced at two levels. First of all, FUS-DDIT3 represses both C/EBPalpha and PPARgamma2 promoters, reducing the expression of both transcription factors. Additionally, the chimeric protein, obstructing the normal translational initiation activity of at least eIF4E, is able to shift towards truncated isoform the expression of C/EBPalpha, reducing its activity and contributing to attenuate the positive feedback loop between C/EBPalpha and PPARgamma that finally results in the expression of mature adipocyte markers such us ap2 or adiponectin (Figure 7). These results will help to develop a strategy that would form the basis for improved therapy in human liposarcomas.
###end p 72
###begin p 73
###xml 378 383 <span type="species:ncbi:9606">human</span>
We thank the members of Lab 13 at IBMCC for advice and criticism and Dr. Teresa Flores for the critical evaluation of histology sections. We are grateful to Dr. Johan Auwerx for the pGL3-hPPARgamma2p1000 vector, to Dr. Achim Leutz for the ratC/EBPalphawtpSG5 and ratC/EBPbetawtpSG5 expression vectors, to Dr. Emmett V. Schmidt for the pm4ECAT vector, to Dr. TH Rabbitts for the human liposarcoma cell lines, to Dr. Ana Perez-Castillo for the pCEBP1171 vector, and to Dr. Bruce Spiegelman for the mPPARgamma2 cDNA.
###end p 73
###begin title 74
References
###end title 74
###begin article-title 75
###xml 40 87 40 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">United States Cancer Statistics: 1999 Incidence</italic>
###xml 25 30 <span type="species:ncbi:9606">Human</span>
Department of Health and Human Services United States Cancer Statistics: 1999 Incidence (Centers for Disease Control and Prevention and National Cancer Institute, Atlanta, 2002)
###end article-title 75
###begin article-title 76
Sarcomas and other malignancies of soft tissue, retroperitoneum, peritoneum, pleura, heart, mediastinum, and spleen.
###end article-title 76
###begin article-title 77
Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11).
###end article-title 77
###begin article-title 78
###xml 49 54 <span type="species:ncbi:9606">human</span>
Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma.
###end article-title 78
###begin article-title 79
Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma.
###end article-title 79
###begin article-title 80
###xml 111 116 <span type="species:ncbi:9606">human</span>
TLS/FUS fusion domain of TLS/FUS-erg chimeric protein resulting from the t(16;21) chromosomal translocation in human myeloid leukemia functions as a transcriptional activation domain.
###end article-title 80
###begin article-title 81
Transcriptional activation by TAL1 and FUS-CHOP proteins expressed in acute malignancies as a result of chromosomal abnormalities.
###end article-title 81
###begin article-title 82
CHOP, a novel developmentally regulated nuclear protein that dimerizes with transcription factors C/EBP and LAP and functions as a dominant-negative inhibitor of gene transcription.
###end article-title 82
###begin article-title 83
Regulated expression of three C/EBP isoforms during adipose conversion of 3T3-L1 cells.
###end article-title 83
###begin article-title 84
The CCAAT/enhancer binding protein and its role in adipocyte differentiation: evidence for direct involvement in terminal adipocyte development.
###end article-title 84
###begin article-title 85
Cascade regulation of terminal adipocyte differentiation by three members of the C/EBP family of leucine zipper proteins.
###end article-title 85
###begin article-title 86
Temperature-dependent localization of TLS-CHOP to splicing factor compartments.
###end article-title 86
###begin article-title 87
A novel effector domain from the RNA-binding protein TLS or EWS is required for oncogenic transformation by CHOP.
###end article-title 87
###begin article-title 88
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human translocation liposarcoma-CCAAT/enhancer binding protein (C/EBP) homologous protein (TLS-CHOP) oncoprotein prevents adipocyte differentiation by directly interfering with C/EBPbeta function.
###end article-title 88
###begin article-title 89
Inhibition of adipogenesis by the stress-induced protein CHOP (Gadd153).
###end article-title 89
###begin article-title 90
Identification of genes differentially expressed in TLS-CHOP carrying myxoid liposarcomas.
###end article-title 90
###begin article-title 91
###xml 78 93 <span type="species:ncbi:10090">transgenic mice</span>
The chimeric FUS/TLS-CHOP fusion protein specifically induces liposarcomas in transgenic mice.
###end article-title 91
###begin article-title 92
Liposarcoma initiated by FUS/TLS-CHOP: the FUS/TLS domain plays a critical role in the pathogenesis of liposarcoma.
###end article-title 92
###begin article-title 93
###xml 127 132 <span type="species:ncbi:9606">human</span>
The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells.
###end article-title 93
###begin article-title 94
###xml 23 38 <span type="species:ncbi:10090">transgenic mice</span>
Fat-specific FUS-DDIT3-transgenic mice establish PPARgamma inactivation is required to liposarcoma development.
###end article-title 94
###begin article-title 95
Expression of the FUS-CHOP fusion protein in primary mesenchymal progenitor cells gives rise to a model of myxoid liposarcoma.
###end article-title 95
###begin article-title 96
###xml 70 85 <span type="species:ncbi:10090">transgenic mice</span>
Expression of the FUS domain restores liposarcoma development in CHOP transgenic mice.
###end article-title 96
###begin article-title 97
Consequences of chromosomal abnormalities in tumour development. Annu. Rev.
###end article-title 97
###begin article-title 98
Understanding mesenchymal cancer: the liposarcoma-associated FUS-DDIT3 fusion gene as a model.
###end article-title 98
###begin article-title 99
Molecular regulation of adipogenesis.
###end article-title 99
###begin article-title 100
Transcriptional regulation of adipogenesis.
###end article-title 100
###begin article-title 101
Adipocyte differentiation from the inside out.
###end article-title 101
###begin article-title 102
A 30-kDa alternative translation product of the CCAAT/enhancer binding protein alpha message: transcriptional activator lacking antimitotic activity.
###end article-title 102
###begin article-title 103
Cascade regulation of terminal adipocyte differentiation by three members of the C/EBP family of leucine zipper proteins.
###end article-title 103
###begin article-title 104
Translational control of C/EBPalpha and C/EBPbeta isoform expression.
###end article-title 104
###begin article-title 105
SLUG (SNAI2) in cancer development .
###end article-title 105
###begin article-title 106
###xml 60 64 <span type="species:ncbi:10090">mice</span>
Cancer development induced by graded expression of Snail in mice.
###end article-title 106
###begin article-title 107
###xml 67 71 <span type="species:ncbi:10090">mice</span>
Sustained leukaemic phenotype after inactivation of BCR-ABLp190 in mice.
###end article-title 107
###begin article-title 108
Adipose tissue mass is modulated by SLUG (SNAI2).
###end article-title 108
###begin article-title 109
###xml 59 64 <span type="species:ncbi:9606">human</span>
The organization, promoter analysis, and expression of the human PPARgamma gene.
###end article-title 109
###begin article-title 110
###xml 47 50 <span type="species:ncbi:10116">rat</span>
###xml 130 133 <span type="species:ncbi:10116">rat</span>
Characterization of the promoter region of the rat CCAAT/enhancer-binding protein alpha gene and regulation by thyroid hormone in rat immortalized brown adipocytes.
###end article-title 110
###begin article-title 111
C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway.
###end article-title 111
###begin article-title 112
Cross-regulation of C/EBP alpha and PPAR gamma controls the transcriptional pathway of adipogenesis and insulin sensitivity.
###end article-title 112
###begin article-title 113
###xml 28 32 <span type="species:ncbi:10090">mice</span>
Adipose tissue reduction in mice lacking the translational inhibitor 4E-BP1.
###end article-title 113
###begin article-title 114
Activated eIF4E-binding protein slows G1 progression and blocks transformation by c-myc without inhibiting cell growth.
###end article-title 114
###begin article-title 115
###xml 117 121 <span type="species:ncbi:10090">mice</span>
A BCR-ABL(p190) fusion gene made by homologous recombination causes B-cell acute lymphoblastic leukemias in chimeric mice with independence of the endogenous bcr product.
###end article-title 115
###begin article-title 116
A retrovirus carrying the promyelocyte-retinoic acid receptor PML-RARalpha fusion gene transforms haematopoietic progenitors in vitro and induces acute leukaemias.
###end article-title 116
###begin article-title 117
PPARgamma knockdown by engineered transcription factors: exogenous PPARgamma2 but not PPARgamma1 reactivates adipogenesis.
###end article-title 117
###begin article-title 118
Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP beta-mediated interleukin 6 expression.
###end article-title 118
###begin article-title 119
Targeting the eukaryotic translation initiation factor 4E for cancer therapy.
###end article-title 119
###begin p 120
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 120
###begin p 121
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: Research in ISG group is supported partially by FEDER and by MEC (SAF2006-03726 and PETRI Ndegrees 95-0913.OP), Junta de Castilla y Leon (CSI03A05), FIS (PI050087, PI050116), Fundacion de Investigacion MMA, Federacion de Cajas de Ahorro Castilla y Leon (I Convocatoria de Ayudas para Proyectos de Investigacion Biosanitaria con Celulas Madre), CDTEAM project (CENIT-Ingenio 2010) and MEC Consolider-Ingenio 2010 (Ref. CSD2007-0017). MSM is supported by the Ramon y Cajal Scientific Spanish Program, Fondo Investigacion Sanitaria (FIS PI04-1271), Junta de Castilla y Leon (SA085A06) and Fundacion Manuel Solorzano, University of Salamanca.
###end p 121

